Search

636 Result(s)
Sort by

Facts About Asthma

Facts About Asthma

Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
PRRS vaccine discovery for swine

PRRS vaccine discovery for swine

PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Zactran®

Zactran®

Depending on species indication (and country of registration), the product is for the treatment and metaphylaxis control of respiratory disease in cattle caused by key bacteria (Mannheimia, Pasteurella, Histophilus and Mycoplasma) and footrot disease
Five facts everyone should know about heartworms

Five facts everyone should know about heartworms

Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
BULTAVO 3

BULTAVO 3

Indicated for bluetongue disease serotype 3 in sheep and cattle
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Transforming Science Day

Transforming Science Day

How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Striverdi® Respimat®

Striverdi® Respimat®

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
NEJM-IL-36-Phase-1-GPP-data

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Ofev®

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million